Emerald Health Therapeutics refers to a licensed enterprise that produces medical marijuana. According to online articles, Emerald brings together essential competencies in combining pharmaceutical innovation with comprehensive agriculture proficiency. Emerald has embarked on a multi-stage expansion. It looks forward to substantial scaling in coping with escalating demand for adult cannabis. The timeline starts on October 17, 2018.
A welcomed development is Health Canada’s approval of Emerald Health Therapeutics partnership with Pure Sun Farms for the conversion of a greenhouse (225,000 square feet out or 1.1 million) for weed production. Completion of the facility is estimated in autumn of 2018. Emerald also purchased Agro-Biotech recently. The latter is a licensed manufacturer in Saint Eustache (Quebec Province).
The indoor hub (75,000 square feet) will supply premium quality marijuana commodities for Quebec as well as markets in Eastern Canada. The country’s health department has also authorized the modular expansion program that sits on a 32-acre location in Vancouver. It will accommodate extraction and processing capabilities. Meanwhile, Emerald will opt for downstream product improvement.
What opportunities can investors expect from Emerald? To start with, the company looks overvalued in line with the comparative valuation model. Company shares may be assessed too high compared to the pharma sector. Stocks are volatile as price movements were overblown compared to the rest of the industry. It indicates prices can still plunge giving investors another opportunity to purchase in the time to come.
How does the future of the company look like? Outlook is always an essential factor when it comes to the acquisition of stocks. This is very relevant for investors projecting growth in their portfolios. Buying stocks in a company that has a buoyant perspective certainly promises a rewarding investment. However, there is always a factor of uncertainty in cannabis companies.
Practical Move for Investors & Shareholders
If you are a stockholder, there are several factors to consider. Emerald can trade below the existing price. Or, it can sell high and purchase back again once the market price declines towards the actual value and turn out profitable. The risk that originates from a negative growth perspective can be the ideal time to lower the risk of the investor’s portfolio.
If you are a prospective investor, observe Emerald carefully since it may not be the right time to buy shares. The price soared further than industry competitors. This does not include the future negative position. It is also a means of observing the market as well as the major players.
For more Cannabis Company Reviews